Alliance Boots to reduce wholesaling division headcount by 10%
This article was originally published in Scrip
Market conditions for Alliance Boots' pharmaceutical wholesale division in the past 12 months have been the most difficult that it has seen, the company says in its preliminary financial results announcement for the year ended March 31st. It has embarked on a restructuring to produce operating cost savings of £55 million per annum by 2011-12, which includes a 10% reduction in headcount in the division.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.